Oncopeptides Valuation Multiples

Oncopeptides Overview

About Oncopeptides

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and, in particular, multiple myeloma.

Founded

2000

HQ

Employees

80

Website

oncopeptides.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $11M

EBITDA: ($22M)

EV

$65M

Valuation Multiples

Multiples.vc

Start free trial

Oncopeptides Financials

Oncopeptides reported last 12-month revenue of $11M and negative EBITDA of ($22M).

In the same LTM period, Oncopeptides generated $10M in gross profit, ($22M) in EBITDA losses, and had net loss of ($24M).

Oncopeptides P&L

In the most recent fiscal year, Oncopeptides reported revenue of $8M and EBITDA of ($25M).

Oncopeptides expects next 12-month revenue of XXX and NTM EBITDA of XXX

Oncopeptides Stock Performance

Oncopeptides has current market cap of $60M, and enterprise value of $65M.

Oncopeptides' stock price is $0.16.

Oncopeptides Valuation Multiples

Oncopeptides trades at 6.0x EV/Revenue multiple, and (2.9x) EV/EBITDA.

Oncopeptides Financial Valuation Multiples

As of April 19, 2026, Oncopeptides has market cap of $60M and EV of $65M.

Equity research analysts estimate Oncopeptides' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Oncopeptides has a P/E ratio of (2.4x).

Oncopeptides Margins & Growth Rates

Oncopeptides' revenue in the last 12 month grew by 89%.

Oncopeptides' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Oncopeptides' rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Oncopeptides' rule of X is 230% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Oncopeptides Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Oncopeptides M&A Activity

Oncopeptides acquired XXX companies to date.

Last acquisition by Oncopeptides was on XXXXXXXX, XXXXX. Oncopeptides acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Oncopeptides Investment Activity

Oncopeptides invested in XXX companies to date.

Oncopeptides made its latest investment on XXXXXXXX, XXXXX. Oncopeptides invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).